Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shing M Lee

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Clinical Trials (London, England)|June 17, 2009
Model calibration in the continual reassessment methodShing M Lee, Ying Kuen Cheung
Statistics in Medicine|March 18, 2011
Calibration of prior variance in the Bayesian continual reassessment methodShing M Lee, Ying Kuen Cheung
Journal of Biopharmaceutical Statistics|March 17, 2017
Selection of the initial design for the two-stage continual reassessment methodXiaoyu Jia, Anastasia Ivanova, Shing M Lee
Journal of Neurosurgery|September 12, 2006
Brain O2Shing M Lee, Dale Hersdorffer, Emilia Bagiella
Statistics in Medicine|December 5, 2019
Incorporating patient-reported outcomes in dose-finding clinical trialsShing M Lee, Xiaoqi Lu, Bin Cheng
Statistics in Medicine|July 2, 2021
Seamless phase I/II design for novel anticancer agents with competing disease progressionLucie Biard, Shing M Lee, Bin Cheng
Journal of Biopharmaceutical Statistics|July 27, 2023
Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollmentAnaïs Andrillon, Lucie Biard, Shing M Lee
Biostatistics (Oxford, England)|September 30, 2010
Continual reassessment method with multiple toxicity constraintsShing M Lee, Bin Cheng, Ying Kuen Cheung
Statistics in Medicine|October 19, 2022
Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progressionAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Journal of Biopharmaceutical Statistics|November 23, 2020
Dose-finding design and benchmark for a right censored endpointAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Clinical Trials (London, England)|June 17, 2009
Model calibration in the continual reassessment methodShing M Lee, Ying Kuen Cheung
Statistics in Medicine|March 18, 2011
Calibration of prior variance in the Bayesian continual reassessment methodShing M Lee, Ying Kuen Cheung
Journal of Biopharmaceutical Statistics|March 17, 2017
Selection of the initial design for the two-stage continual reassessment methodXiaoyu Jia, Anastasia Ivanova, Shing M Lee
Journal of Neurosurgery|September 12, 2006
Brain O2Shing M Lee, Dale Hersdorffer, Emilia Bagiella
Statistics in Medicine|December 5, 2019
Incorporating patient-reported outcomes in dose-finding clinical trialsShing M Lee, Xiaoqi Lu, Bin Cheng
Statistics in Medicine|July 2, 2021
Seamless phase I/II design for novel anticancer agents with competing disease progressionLucie Biard, Shing M Lee, Bin Cheng
Journal of Biopharmaceutical Statistics|July 27, 2023
Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollmentAnaïs Andrillon, Lucie Biard, Shing M Lee
Biostatistics (Oxford, England)|September 30, 2010
Continual reassessment method with multiple toxicity constraintsShing M Lee, Bin Cheng, Ying Kuen Cheung
Statistics in Medicine|October 19, 2022
Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progressionAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Journal of Biopharmaceutical Statistics|November 23, 2020
Dose-finding design and benchmark for a right censored endpointAnaïs Andrillon, Sylvie Chevret, Shing M Lee, et al.
Pageof 7